
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics is a clinical-stage pharmaceutical company with a positive outlook, due to its promising pipeline of potential products targeting CNS cancers and rare diseases. The recent reverse stock split is deemed to have a risk/reward positive effect, as the company maintains its BUY rating with lowered 12-month price target, indicating significant upside potential. The recent Q4 results showcase the company's revenue growth and its focus on clinical trials for its lead candidate, REYOBIQ, an innovative treatment for GBM and LM. Additionally, the recent ISPOR analysis supports the economic value proposition of Plus Therapeutics' CNSide platform, which can potentially reduce healthcare costs by about 40%. The company is also focused on commercializing and scaling up manufacturing for REYOBIQ, expanding reimbursement coverage, and driving test volume growth.
Bears say
Plus Therapeutics is facing potential headwinds with its recent downgrade to Hold and a newly announced reverse stock split, indicating possible struggles to meet listing compliance and pressures on trading liquidity. While the company received major grant wins in 2022 and 2024, it continues to face significant EPS losses and could face difficulties in enrolling patients in its LM trial, casting doubts on its ability to successfully commercialize its main drug candidate, REYOBIQ.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares